What is Adicet Bio?
Adicet Bio is a pre-clinical stage biotechnology firm dedicated to the design and development of allogeneic immunotherapies. Established in 2014 and headquartered in Boston, MA, the company focuses on harnessing the power of the immune system to combat complex diseases, particularly in the oncology space. Its pipeline of engineered T-cell therapies aims to provide off-the-shelf solutions, differentiating it from traditional autologous approaches. The company's strategic direction is geared towards translating its scientific discoveries into viable therapeutic options for patients with unmet medical needs.
How much funding has Adicet Bio raised?
Adicet Bio has raised a total of $218M across 3 funding rounds:
Series A
$51M
Series B
$80M
Stock Offering
$87M
Series A (2016): $51M with participation from OrbiMed, Novartis Venture Fund, and Pontifax
Series B (2019): $80M led by Novartis Venture Fund, Pontifax, OrbiMed Israel, and OrbiMed Partners
Stock Issuance/Offering (2021): $87M, investors not publicly disclosed
Key Investors in Adicet Bio
Novartis Venture Fund
Novartis Venture Fund is a venture capital arm of Novartis, a global pharmaceutical giant. They specialize in investing in innovative healthcare and life sciences companies, focusing on early-stage to late-stage ventures that align with Novartis's strategic interests in drug discovery and development.
Pontifax
Pontifax Venture Capital is a prominent investment firm dedicated to the life sciences sector. They actively seek out and support transformative healthcare technologies, providing strategic guidance and capital to companies across various stages of development, with a particular emphasis on clinical-stage ventures.
OrbiMed
OrbiMed Advisors LLC is a leading global investment firm focused exclusively on the healthcare industry. They manage capital across a broad spectrum of healthcare sub-sectors, including biopharmaceuticals, medical devices, and healthcare services, supporting companies from early-stage innovation to commercial expansion.
What's next for Adicet Bio?
The recent major strategic investment positions Adicet Bio for accelerated growth and the advancement of its pre-clinical pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to move key programs towards clinical trials. Adicet Bio's focus on allogeneic immunotherapies suggests a long-term strategy aimed at establishing a scalable platform for cancer treatment. The company's trajectory indicates a commitment to innovation and a drive to capture significant market share in the rapidly evolving field of immuno-oncology.
See full Adicet Bio company page
